Navigation Links
Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients

Maxygen, Inc. today announced that it has initiated a phase IIa trial to evaluate the efficacy, safety and tolerability of MAXY-G34 in the treatment of chemotherapy-induced neutropenia . MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) shown in preclinical and Phase I studies to have novel and potentially superior properties compared to the current PEG- GCSF therapy.

"Patients and physicians have limited options for treatment of neutropenia," said Russell Howard, chief executive officer of Maxygen. "With MAXY-G34, we hope to expand those options and improve the outcome for many chemotherapy patients. During this first Phase II trial we will begin to learn more about how our drug might play a role in the large, undifferentiated GCSF market."

The Phase IIa trial, which will be conducted at multiple centers in Eastern Europe, is the first trial of MAXY-G34 in patients. Approximately 30 patients with Stage I-III breast cancer will undergo TAC (docetaxel, adriamycin and cyclophosphamide) chemotherapy followed by next-day administration of either MAXY-G34 or Neulasta (control population). The trial is designed as a multiple ascending dose study, with planned doses at 10, 30, 60, or 100 micrograms per kilogram of MAXY-G34 compared to 6mg of Neulasta. Both MAXY-G34 and Neulasta will be administered as a single subcutaneous injection once per chemotherapy cycle.

The primary objective of the Phase IIa trial is to identify one or more doses of MAXY-G34 that effectively treat chemotherapy-induced neutropenia. Patient tolerability, safety, and immunogenicity will be monitored and assessed. Data will also be collected on the pharmacokinetic properties of MAXY-G34 and the mobilization of CD34+ stem cells.

Phase I Results

A Phase I trial was previously conducted to assess the safety and tolerability of MAXY-G34 in 40 healthy volunteers. This study showed MAXY-G34 to be a potent
'"/>




Page: 1 2

Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
6. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
7. SARS-Free Taiwan to Mark End Phase of Global Fight
8. Spray on contraceptive clears Phase I trial
9. Phase 3 trials of two multi-kinase inhibitors against cancer
10. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
11. Phase II trails of new HIV vaccine to be held in South Africa
Post Your Comments:
(Date:7/12/2014)... Security Analytics market is estimated to grow from $1,961.8 ... an expected CAGR of 9.7% for the period between ... number of security breaches, continued line of sophisticated attacks, ... are enormous. Vendors in the security analytics market are ... better and more secure systems. , There has been ...
(Date:7/12/2014)... July 12, 2014 Casinos ... despite rising competition from international and online casinos. Revenue ... over the five years through 2014-15. Greater per capita ... more gaming services. Rises in discretionary income levels have ... money on non-essential items such as casino gambling services. ...
(Date:7/12/2014)... 12, 2014 "The second toes cross over ... painful to wear shoes," said an inventor from East Hartford, ... prevents this from happening. , He then created a prototype ... prevent the second and big toes from overlapping. This avoids ... shoes. Ergonomic and easy to use, it's ideal for people ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... 2014 For those who are unfamiliar with ... absorb the nutrients in food. The enzymes literally break up ... enough to be absorbed by human bodies. According Dr. Henry ... enzymes in regular food is the cause of many gastrointestinal ... started by Michelle DelPresto, a mother of 3 who is ...
Breaking Medicine News(10 mins):Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2
... 2011-For many young scientists, particularly women, research careers hang ... that the American Society for Cell Biology (ASCB) hopes ... grant from Nature Publishing Group (NPG) to underwrite childcare ... next five years. The awards help ensure the continuation ...
... Salk Institute for Biological Studies have found clues to the ... protein, p53, can cause cells to stop dividing or even ... and it is responsible for much of the tissue destruction ... as the ones commonly used for cancer therapy. The new ...
... News) -- Parents who smoke are more likely to try to ... chances of success aren,t any better than normal, a new study ... role in helping these parents quit smoking, said the researchers at ... children who lived with at least one person who smoked in ...
... than whites to receive critical stroke treatment primarily because ... for time-sensitive treatment and because of preexisting medical conditions. ... racial disparity was found. Those are the findings ... the review of almost 1,000 patient records from all ...
... Reporter , THURSDAY, June 30 (HealthDay News) -- You,re probably ... never happened, especially if you,re around people who recall things ... novel false-memory test and brain-scanning technology to find out how ... took part in the test believed the implanted memories -- ...
... DIEGO, CA In order to recognize and encourage ... the American Orthopaedic Society for Sports Medicine (AOSSM) will ... Annual Meeting, July 7-10 in San Diego, California. ... provides more than $300,000 to research initiatives and projects ...
Cached Medicine News:Health News:Nature Publishing Group supports ASCB Childcare Awards for scientist-parents at annual meeting 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 3Health News:A Child's Surgery May Prompt Parents to Try to Quit Smoking 2Health News:Georgetown research identifies key reasons racial disparities exist in emergent stroke treatment 2Health News:Group-Think Can Influence Your Memory, Research Shows 2Health News:AOSSM presents prestigious research awards at annual meeting 2Health News:AOSSM presents prestigious research awards at annual meeting 3Health News:AOSSM presents prestigious research awards at annual meeting 4
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ("Neurelis") ... to end the option held by Biotie to purchase ... development of NRL-1 (intranasal diazepam) for pediatric and adult ... Over the past year, Biotie has advanced the development ... for the pivotal clinical work required for NDA submission ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., a ... has launched the FreeRunner™ knee brace with new ... from patella mal-tracking return to active lifestyles.  FreeRunner,s ... other braces, providing support when patients need it ... they don,t. Patellofemoral issues are the ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 2011 PRA International, a leading Clinical Research Organization, announces ... upcoming Partnerships in Clinical Trials and Late Phase Drug Development ... Mike Hill, Project Manager for PRA,s Late Phase Services ... Development conference in Boston, MA on 23 March at 11:10 ...
... March 23, 2011 NephRx Corporation today announced ... novel peptide NX002, which currently is in preclinical ... NephRx reported that NX002 had demonstrated significant efficacy ... mucositis.  Mucositis is a debilitating and often dose-limiting ...
Cached Medicine Technology:PRA International Experts to Speak at Industry Events 2NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002 2NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002 3
... positive locking rail mounting system features a ... up and down movement, adjusting the armboard ... changing the pad. The Armboard provides easy ... of O.R. Table, and the secure positive ...
... carbon fiber armboard is easily ... table siderail. Durable construction eliminates ... enclosed within molded body, protecting ... Molded carbon fiber allows for ...
Inquire...
Stainless steel construction to withstand sterilization modalities (autoclave, EtO, Steris®, and Sterrad®) Fully autoclavable, with both distal and proximal ends uniquely soldered for longe...
Medicine Products: